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Abstract 
Background: Shigella, gram negative bacterium, is responsible for Shigellosis/bacillary dysentery. It is a global con-
cern although it predominates in developing countries. These are Shigella dysenteriae, Shigella flexneri, Shigella boydii 
and Shigella sonnei. Drug resistance by Shigella species is another headache of the world. Therefore; this study aimed 
to review distribution of Shigella Serogroups and their antimicrobial patterns carried out in Africa, Asia and South 
America.
Methods: A literature search was performed to identify published studies between January 2001 and December 
2014. Published studies were identified using an initial search of the MEDLINE/Index Medicus Database, PubMed, 
Project Management Consultant, Google Scholar, Science Direct, BioMed Central and Index Copernicus.
Results: Shigella flexneri was isolated predominately from seven studies in four African countries and eight studies 
in five Asian countries. The countries in which eligible studies carried out were Ethiopia, Kenya, Eritrea and Ghana 
in Africa and Pakistan, Iran, China, Nepal and India in Asia. S. sonnei was isolated predominately from one study in 
Africa, four in Asia and two South America. The countries in which eligible studies carried out were Ethiopia from 
Africa, Thailand, Vietnam and Iran from Asia and Chile and Trinidad from South America. S. dysentery was also reported 
majorly from one eligible study in Egypt and one in Nepal. S. boydii did not score highest prevalence in any one of the 
eligible studies. Three studies from Africa, five from Asia and one from South America were reviewed for antimicrobial 
resistance patterns of Shigella Serogroups. In all the regions, Ampicillin developed highly resistance to almost all the 
Serogroups of Shigella whereas all the strains were sensitive to Ciprofloxacin.
Conclusion: The incidence of Shigella Serogroups in the selected three regions is different. The domination of 
S. flexneri is observed in Africa and Asia although S. sonnei in South America is dominant. Shigella Serogroups are 
becoming resistance to the commonly prescribed antimicrobial drugs in developing countries.
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Background
Shigella, a group of Gram-negative, non-spore forming 
and rod shaped bacterium, is the causative agent of shig-
ellosis (or bacillary dysentery). Shigella Serogroups are 
considered to be highly infectious due to their low infec-
tious dose (10–100 organisms) [1]. Shigella is primar-
ily transmitted through the fecal-oral route; therefore, it 
is still a main global public health threat, particularly in 
developing countries due to poor sanitation conditions [2].
Shigella bacteria are serologically grouped into four 
species named as Shigella dysenteriae, Shigella flexneri, 
Shigella boydii and Shigella sonnei. However Serogroups 
of Shigella bacteria have similar property of pathogenesis 
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and epidemiologically they have peculiar characteristics. 
S. flexneri found predominantly in developing world, 
while S. sonnei is the most common species found in the 
industrialized countries [3]. The severity of Serogroups 
of Shigella is different one from the other that S. sonnei 
and S. flexneri cause mild infection whereas S. boydii and 
S. dysenteriae cause severe and most serious infection 
respectively [2]. The infection caused by S. sonnei and 
S. boydii lasts with short duration and mostly found in 
industrialized countries. The distribution of Shigella son-
nei in the United States of America is 74–79  % [4] and 
61 % in Europe [5].
The emerging of multi drug resistance is becoming a 
serious problem in the treatment of shigellosis. An incre-
ment of multidrug resistance to shigellosis is equivalent 
to a widespread uncontrolled use of antibiotics in devel-
oping countries. This emergency of drug resistance calls 
for the rational use of effective drugs and underscores the 
need for alternative drugs to treat infections caused by 
resistant strains [6].
Shigella is more associated with low socio economic 
status and poor sanitation of under developed countries 
[2]. Researches were done by different researchers con-
cerning the Serogroups and antimicrobial susceptibility 
patterns of Shigella in Africa, Asia and South America as 
a result this study aimed in reviewing the distribution of 
Serogroups of Shigella and the resistance patterns of anti-
microbial drugs which were conducted in the developing 
countries in the past 14 years.
Methods
Search strategy and selection criteria
A literature search was performed to identify published 
studies between January 2001 and December 2014. Pub-
lished studies were identified using an initial search of 
the MEDLINE/Index Medicus Database, PubMed, PMC, 
Google Scholar, Science Direct, BioMed Central and 
Index Copernicus.
The study initially screened all unique publications for 
eligibility based on the relevancy of the title and then 
screened the full manuscripts for inclusion and exclusion 
criteria. The following Keywords were used to search 
all the published papers from the above engines. These 
were Prevalence, isolation, Sero diversity, occurrence, 
epidemiology, Magnitude, burden, estimation, distribu-
tion, diversity and antimicrobial resistance patterns of 
Shigella. Studies conducted before 2001 and researches 
which concerned only prevalence and antimicrobial sus-
ceptibility patterns of Shigella were excluded.
Data extraction
The first author, country, year of publication, set-
ting, sample size, children and all age, sample source, 
prevalence and distribution of Serogroups of Shigella 
were extracted from the eligible studies. Ampicillin, Tet-
racycline, Chloramphenicol, Ciprofloxacin, Cotrimoxa-
zole, Nalidixic acid and Gentamicin resistance patterns of 
the four Sero groups of Shigella were extracted from the 
eligible studies.
Studies were included in the review if they fulfill the 
following criteria:
  • Isolation and identifying of Shigella from stool sam-
ples should be based on standard bacteriological 
methods and Shigella Serogroups were detected 
serologically using slide agglutination and antimicro-
bial resistance patterns of Shigella Serogroups should 
be based on Clinical Standards Laboratory Institute 
guidelines using disc diffusion methods.
  • Full text articles studied in Africa, Asia, and South 
America and published in English everywhere in the 
globe were included.
Results
Majority of the reviewed articles were Hospital based 
studies. About 40  % of the study participants were 
children under 15  years old. Stool samples were the 
source of specimens in all the eligible studies. A total 
of 69,849 stool specimens’ data were collected. Eight-
een (72 %) of the eligible studies were published before 
2010 and the rest seven were published from 2010 to 
2014 (Table 1).
Shigella flexneri was isolated predominately from Ethi-
opia [7, 8, 14], Kenya [9, 13], Eritrea [11], Ghana [12], 
Pakistan [16], Iran [17, 22], China [19, 27], Nepal [23, 
28], India [29] and Brazil [31] (Table 1). S. sonnei was also 
isolated predominately from Ethiopia [13], Thailand [18], 
Vietnam [24] and Iran [25, 26], Chile [21] and Trinidad 
[30]. S. dysentery was also reported majorly from Egypt 
[10] and Nepal [15]. S. boydii did not score highest preva-
lence in any one of the eligible studies (Table 1).
Shigella sonnei was not isolated from studies con-
ducted in Ethiopia [14] and Nepal [20]. S. dysentery was 
not isolated from the studies conducted in Ethiopia [14], 
Thailand [18], China [19, 27], Chile [21], Brazil [31], and 
Vietnam [24]. S. boydii was not also isolated from the 
studies conducted in Ethiopia [14], Eritrea [11], Thailand 
[18], China [19, 27], Chile [21] and Brazil [31] (Table 1).
Nine studies were eligible for antimicrobial susceptibil-
ity testing [AST] of Shigella Serogroups. Those are three 
from Africa, five from Asia and one from South America. 
In all the regions, Ampicillin developed highly resist-
ance to almost all the Serogroups of Shigella whereas 
all the strains were sensitive to Ciprofloxacin. Hundred 
percent of isolates revealed by Orrette in South Amer-
ica were resistance for Ampicillin but 100 % sensitive to 
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Tetracycline, Chloramphenicol, Ciprofloxacin and Cot-
rimoxazole (Table 2). In most of the studies observed in 
Africa (Table  3) and Asia (Table  4), Serogroups of Shi-
gella were developed resistance to Tetracycline, Chlo-
ramphencol and Cotrimoxazole.
Discussion
This review addressed the status of the distribution of 
the Serogroups of Shigella and antimicrobial resistance 
patterns conducted in 25 eligible studies reviewed from 
Africa, Asia and South America.
Shigella flexneri was revealed 100  % from all the eli-
gible studies reviewed in eight African, fourteen Asian 
and three South American countries. S. dysentery was 
reviewed from 87, 72 and 33 % of the eight African, four-
teen Asian and three South American countries respec-
tively. S. boydii was reviewed from 75, 79 and 33  % of 
the studies carried out in eight Africa, fourteen Asia 
and three South America respectively. S. sonnei was also 
reviewed in 87, 86 and 100  % of the studies conducted 
in eight Africa, fourteen Asia and three South American 
countries respectively (Table 1).
Of the total 69,849 stool sample data collected from the 
25 eligible studies published from 2001 to 2014, 4027 Shi-
gella bacteria were isolated which is 5.8 %. Above 50 % of 
the proportion of Shigella Serogroups was covered by S. 
flexneri which was followed by S. sonnei (33  %). S. boy-
dii was contributed five percent of the four Serogroups of 
Shigella (Table 1).
The pooled mean resistance of S. dysentriae to Ampi-
cillin, Tetracycline, Cotrimoxazole, Chloramphenicol, 
Nalidix acid, Gentamicin and Ciprofloxacin were 72.1, 
69.4, 60, 44, 40, 17 and 7 % respectively. The pooled mean 
resistance of S. flexneri to Tetracycline, Ampicillin, Nali-
dix acid, Cotrimoxazole, Chloramphenicol, Gentamicin 
and Ciprofloxacin were 75.8, 75.6, 74.5, 72.7, 51.7, 14.5 
and 7  % respectively. The pooled mean resistance of S. 
boydii to Ampicillin, Tetracycline, Cotrimoxazole, Chlo-
ramphenicol, Ciprofloxacin, Gentamicin and Nalidix acid 
were 64, 63, 48, 29, 10, 6 and 3 % respectively. The pooled 
mean resistance of S. sonnei to Tetracycline, Cotrimoxa-
zole, Nalidix acid, Ampicillin, Chloramphenicol, Gen-
tamicin and Ciprofloxacin were 79, 71, 54, 47, 35, 16 and 
0 % respectively (Table 5).
Table 2 Review on antimicrobial resistance patterns of Serogroups of Shigella conducted in South America
Author Serogroup Resistance patterns, N (%)
AMP T C CIP NA SXT GM
Orrett [30] S. dysentery 7 (100) 0 (0.0) 0 (0.0) 0 (0.0) – 0 (0.0) 0 (0.0)
S. flexneri 36 (46) 9 (12) 0 (0.0) 0 (0.0) – 16 (21) 0 (0.0)
S. boydii 10 (63) 6 (38) 3 (3.9) 0 (0.0) – 3 (19) 0 (0.0)
S. sonnei 27 (9) 106 (36) 4 (1.4) 2 (0.7) – 97 (33) 4 (1.4)
Table 3 Review on antimicrobial resistance patterns of Serogroups of Shigella conducted in Africa
Authors Serogroups Resistance patterns, N(%)
AMP T C CIP NA SXT GM
Mache [8] S. dysentery 17 (73.9) 15 (64.2) 12 (52.2) – 11 (8.7) 9 (39.1) 0 (0.0)
S. flexneri 22 (71) 20 (64.5) 13 (41.9) – 3 (9.7) 9 (29) 1 (3.2)
S. boydii 10 (66.7) 8 (53.3) 4 (25) – 0 (0.0) 5 (33.3) 0 (0.0)
S. sonnei 5 (62.5) 6 (75) 2 (25) – 0 (0.0) 2 (25) 0 (0.0)
Tiruneh [6] S. dysentery 8 (89) 7 (77.8) 1 (11) 0 (0.0) 0 (0.0) 7 (77.8) 1 (11)
S. flexneri 54 (83) 62 (95.4) 45 (69) 2 (31) 0 (0.0) 59 (90.8) 7 (10.8)
S. boydii 4 (50) 7 (87.5) 2 (25) 0 (0.0) 0 (0.0) 4 (50) 2 (25)
S. sonnei 3 (37.5) 8 (100) 2 (25) 0 (0.0) 0 (0.0) 6 (75) 1 (12.5)
Naik [11] S. dysentery 19 (95) – 18 (90) 0 (0.0) – 0 (0.0) –
S. flexneri 42 (78) – 34 (67) 0 (0.0) – 3 (6) –
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Above 50  % of all Serogroups of Shigella developed 
resistance to Ampicillin, Tetracycline, Cotrimoxazole and 
Chloramphenicol which are the commonly prescribed 
antimicrobial drugs.
Conclusions
The incidence of Shigella Serogroups in the selected 
three regions is different. The domination of S. flexneri is 
observed in Africa and Asia although S. sonnei, the most 
dominant in South America, is predominately isolated in 
one study in Ethiopia. This may give clue to the scientific 
world about the migration and movement of strains from 
one region to the other region. Shigella Serogroups are 
becoming resistance to the commonly prescribed antimi-
crobial drugs in developing countries.
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Table 4 Review on antimicrobial resistance patterns of Serogroups of Shigella conducted in Asia
Author Serogroups Resistance patterns, N (%)
AMP T C CIP NA SXT GM
Wang [19] S. flexneri 292 (95.4) – – 18 (5.9) 305 (99.7) 206 (67.3) 7 (2.3)
S. sonnei 2 (8) – – 0 (0.0) 24 (96) 24 (96) 0 (0.0)
Bhattacharya [20] S. dysentery 32 (82.1) – – 13 (33.3) 33 (84.6) 35 (89.5) –
S. flexneri 12 (100) – – 2 (16.7) 4 (33.3) 11 (91.7) –
S. boydii 2 (100) – – 1 (50) 0 (0.0) 1 (50) –
Mashouf [22] S. dysentery 54 (96.4) 50 (89.2) 52 (92.8) 3 (3.5) 48 (85.7) 52 (92.8) –
S. flexneri 63 (94) 61 (91.1) 61 (91.1) 0 (0.0) 3 (44.7) 59 (88.1) –
S. boydii 17 (68) 13 (52) 21 (84) 0 (0.0) 0 (0.0) 15 (60) –
S. sonnei 15 (83.3) 15 (83.3) 17 (94.4) 0 (0.0) 7 (38.8) 14 (77.7) –
Wilson [23] S. dysentery 6 (75) 7 (87.5) 5 (62.5) 1 (12.5) 5 (62.5) 51 (100) 6 (75)
S. flexneri 33 (64.7) 49 (96) 23 (45.1) 1 (2) 16 (31.4) 8 (100) 34 (66.7)
Jafari [26] S. dysentery 3 (37.5) 8 (100) 0 (0.0) 0 (0.0) 0 (0.0) 7 (87.5) 0 (0.0)
S. flexneri 23 (47.9) 46 (95.8) 23 (47.9) 0 (0.0) 0 (0.0) 42 (87.5) 2 (4)
S. boydii 5 (38.4) 11 (84.6) 1 (7.6) 0 (0.0) 2 (15.4) 10 (76.9) 0 (0.0)
Table 5 Pooled range and mean of antimicrobial resistance patterns of Shigella Serogroups
AMP Ampicillin, T Tetracycline, C Chloramphenicol, CIP Ciprofloxacin, NA Nalidixic acid, SXT sulphamethoxazole trimethoprim/Cotrimoxazole, GM gentamicin, PR 




AMP T C CIP NA SXT GM
PR PM PR PM PR PM PR PM PR PM PR PM PR PM
S. dysentery 37.5−100 72.1 0−100 69.4 0−92.8 44.1 0−33.3 7 0−85.7 40.3 0−100 60.8 0−75 17.2
No. of studies 8 6 7 7 6 8 5
S. flexneri 46−100 75.6 12−95.8 75.8 0−91.1 51.7 0−31 7 0−99.7 74.1 6−100 72.7 0−66.7 14.5
No. of studies 9 6 7 8 7 9 6
S. boydii 38.4−100 64.4 38−87.5 63.1 3.9−84 29.1 0−50 10 0−15.4 3.1 19−76.9 48.2 0−25 6.3
No. of studies 6 5 5 5 5 6 4
S. sonnei 8−83.3 46.9 36−100 79.4 1.4−94.4 35.4 0−0.7 0.12 0−96 54.8 25−100 71.9 0−12.5 16.6
No. of studies 7 6 6 6 6 6 6
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